MANTRA-PAF研究显示在减少心房颤动（房颤）负荷或发作方面，射频消融优于抗心律失常药物。研究提示；对于平均年龄55岁，无较多伴随疾病的阵发性房颤患者，射频消融可作为首选治疗。
　　The MANTRA-PAF trial was conducted in paroxysmal atrial fibrillation (AF) patients， and the trial showed that radiofrequency (RF) ablation is superior to antiarrhythmic drugs in terms of reducing the AF burden or the occurrence of AF. The trial can help us to inform the patients that， if the patients are like our patients here--pretty young， they were a mean 55 years old and without much comorbidity--such patients， if they prefer ablation， you can first inform them that ablation is at least as good as drug treatment. But they have to be aware that there are some risks in doing ablation procedures. If they， after this information， still want to undergo ablation， then it’s a reasonable treatment as a first time treatment， but only in these selected patients.